Advertisement
News
Advertisement

GeNO gets NDA review in second NO-based device

Wed, 11/14/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

A new drug application for GeNO LLC’s second product designed to delivery nitric oxide to newborn babies for treatment of respiratory failure has been accepted for review by the U.S. Food and Drug Administration.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading